Robert W. Lee is vice president of pharmaceutical development and quality at Particle Sciences in Bethlehem, Pennsylvania. Lee received a PhD in physical bioorganic chemistry from the University of California in Santa Barbara, California. He has published numerous articles in peer-reviewed journals and three book chapters, and he holds 11 issued patents and 14 provisional or PCT patent applications.
Eugene R. Cooper is a pharmaceutical consultant in Berwyn, Pennsylvania. He received a PhD from Iowa State University in theoretical physical chemistry and was a National Science Foundation (NSF) postdoctoral fellow. He is the founder of several drug delivery companies, has worked as a senior manager of pharmaceutical research and development, and has led development of nanoparticle technology for the pharmaceutical industry, beginning with NanoSystems.
Chris Bode is vice president of scientific and corporate communications at Absorption Systems in Exton, Pennsylvania. He received his PhD in pharmacology from the University of Colorado and performed postdoctoral research in the departments of pharmacology and medicine at the University of California in San Diego, California. He possesses 22-plus years of experience in research and development.
CDs are non-returnable/non-refundable
Transdermal is the only technical publication devoted exclusively to readers involved in development and production of pharmaceuticals delivered through the skin.
Webinars
Selection of Active Pharmaceutical Ingredients (APIs) and Excipients for Topical Formulations and Methods of Evaluating the Formulations, 9/11
CD of live broadcast 9/20/11
Transdermal drug delivery is a viable option for systemic delivery of select drugs. It provides advantages, such as avoidance of first-pass metabolism, patients’ improved compliance, controlled or sustained release, and decreased side effects. This webinar focuses on transdermal delivery via application of a topical, semisolid formulation in the form of a gel, lotion, or cream. The presenters will discuss selection criteria for APIs, excipient selection and compatibility screening, formulation development and optimization, and the use of in-vitro and in-vivo preclinical screening tools for identification of lead formulation candidates. This is an excellent webinar for the basics of topical delivery.
Moderator: Peggy Wright, Editor of Transdermal
Presenters: Robert Lee, PhD, Eugene Cooper, PhD and Chris Bode, PhD
Transdermal drug delivery is a viable option for systemic delivery of select drugs. It provides advantages, such as avoidance of first-pass metabolism, patients’ improved compliance, controlled or sustained release, and decreased side effects. This webinar focuses on transdermal delivery via application of a topical, semisolid formulation in the form of a gel, lotion, or cream. The presenters will discuss selection criteria for APIs, excipient selection and compatibility screening, formulation development and optimization, and the use of in-vitro and in-vivo preclinical screening tools for identification of lead formulation candidates. This is an excellent webinar for the basics of topical delivery.
Moderator: Peggy Wright, Editor of Transdermal
Presenters: Robert Lee, PhD, Eugene Cooper, PhD and Chris Bode, PhD
Return Policy:
I understand that I may return these books within 15 days from the date of purchase for a full refund (offer valid in North America only). Does not apply to DVD/CDs.
Security:
Your payment information is forwarded in an encrypted form, using 40- or 128-bit Secure Socket Layer technology, only to our payment gateway (Authorize.net) for processing.